Co-founder of Arm attacks sale to Nvidia as a “disaster”

admin

Co-founder of Arm attacks sale to Nvidia as a “disaster” (Updates with Hauser interview) LONDON, Sept 14 (Reuters) – The $40 billion sale of British chip designer Arm to Nvidia Corp from Japan’s SoftBank is a disaster that will destroy its business model, Arm’s co-founder said on Monday.”It’s a disaster for Cambridge, the UK and…

Co-founder of Arm attacks sale to Nvidia as a “disaster” (Updates with Hauser interview) LONDON, Sept 14 (Reuters) – The $40 billion sale of British chip designer Arm to Nvidia Corp from Japan’s SoftBank is a disaster that will destroy its business model, Arm’s co-founder said on Monday.”It’s a disaster for Cambridge, the UK and Europe,” Hermann Hauser told Reuters in an interview.”It’s the last European technology company with global relevance and it’s being sold to the Americans.” The deal announced overnight would destroy Arm’s business model as “the Switzerland of the semiconductor industry”, Hauser said.Nvidia competes with Arm’s clients.Hauser called on the UK government to put three conditions on the deal: a guarantee of jobs in Britain; a promise to preserve ARM’s open business model; and an exception to U.S.security reviews on its client relationships.

If these could not be met, “the British government should help orchestrate an initial public offering of ARM on the London Stock Exchange and make it a British company”, Hauser said, urging the UK to back a market float as a cornerstone investor.

(Reporting by Kate Holton and Douglas Busvine; editing by Michael Holden and William Schomberg) First Published: 2020-09-14 08:37:03 Updated 2020-09-14 09:04:26
© 2020 Thomson Reuters.

All rights reserved.Reuters content is the intellectual property of Thomson Reuters or its third party content providers.Any copying, republication or redistribution of Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.Thomson Reuters shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon.

“Reuters” and the Reuters Logo are trademarks of Thomson Reuters and its affiliated companies.Most read today What is RSS? » Risk Disclosure: Sharenet will not accept any liability for loss or damage as a result of reliance on the information contained within this website including data, quotes, charts and buy/sell signals.Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.Currency trading on margin involves high risk, and is not suitable for all investors.

Trading or investing in crypto currencies carries with it potential risks.Prices of crypto currencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events.Crypto currencies are not suitable for all investors.Before deciding to trade foreign exchange or any other financial instrument or crypto currencies you should carefully consider your investment objectives, level of experience, and risk appetite.Sharenet would like to remind you that the data contained in this website is not necessarily real-time nor accurate.

All CFDs (stocks, indexes, futures), Forex and crypto currencies prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes.Therefore Sharenet doesn’t bear any responsibility for any trading losses you might incur as a result of using this data.Sharenet may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

Market Statistics are calculated by Sharenet and are therefore not the official JSE Market Statistics.

The calculation/derivation may include underlying JSE data.Sharenet Group of Companies are authorised financial services providers.Sharenet Securities FSP#: 28430 | Sharenet Wealth FSP#: 41688 © 2020 SHARENET (PTY) Ltd, Cape Town, South Africa.

Leave a Reply

Next Post

AstraZeneca shares rise as UK coronavirus vaccine trial resumes

Most Read AstraZeneca shares rise as UK coronavirus vaccine trial resumes Sept 14 (Reuters) - Shares of AstraZeneca rose 1% to 8,516 pence on Monday after the British drugmaker received the go-ahead from safety watchdogs over the weekend to resume clinical trials for its COVID-19 vaccine candidate in the United Kingdom.The resumption of the trials…
AstraZeneca shares rise as UK coronavirus vaccine trial resumes

Subscribe US Now